Benitec Biopharma (BNTC) shares full-year 2025 results and operations update

Rhea-AI Filing Summary

Benitec Biopharma Inc. furnished an update on its business by issuing a press release with financial results for its full year ended June 30, 2025 and an operational update. The company attached this press release as Exhibit 99.1 to the current report and specified that this information is being furnished under the results of operations and financial condition item, rather than treated as filed for liability purposes or automatically incorporated into other documents.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001808898false00018088982025-09-222025-09-22

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 22, 2025

Benitec Biopharma Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39267	84-4620206
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
3940 Trust Way
Hayward, California				94545
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (510) 780-0819

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001		BNTC		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On September 22, 2025, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its full year ended June 30, 2025 and providing an operational update. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, the information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this Item 2.02 shall not be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference into such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Press Release of Benitec Biopharma Inc. dated September 22, 2025

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			benitec biopharma inc.
Date:	September 22, 2025	By:	/s/ Dr. Jerel A. Banks
			Name: Dr. Jerel A. Banks Title: Chief Executive Officer

FAQ

What did Benitec Biopharma Inc. (BNTC) announce in this 8-K?

Benitec Biopharma Inc. reported that it issued a press release with its financial results for the full year ended June 30, 2025 and provided an operational update, which is included as Exhibit 99.1.

Which period do Benitec Biopharma's latest results cover?

The reported financial results cover Benitec Biopharma Inc.’s full year ended June 30, 2025.

How are the Benitec Biopharma (BNTC) results treated for SEC liability purposes?

The company states that the information furnished, including Exhibit 99.1, is not deemed filed for purposes of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act.

Is the Benitec Biopharma full-year 2025 press release automatically incorporated into other filings?

No. Benitec Biopharma specifies that the information furnished, including Exhibit 99.1, will not be incorporated by reference into other filings unless expressly incorporated by specific reference.

What exhibit contains Benitec Biopharma Inc.’s full-year 2025 results and update?

The press release with the full-year financial results and operational update is included as Exhibit 99.1.

On which stock exchange is Benitec Biopharma Inc. (BNTC) listed?

Benitec Biopharma Inc.’s common stock, par value $0.0001, trades on The Nasdaq Stock Market LLC under the symbol BNTC.